Year Published
- (-) Remove 2008 filter 2008
- 2009 (0)
- (-) Remove 2010 filter 2010
- 2011 (1) Apply 2011 filter
- 2012 (0)
- 2013 (0)
- 2014 (2) Apply 2014 filter
- (-) Remove 2015 filter 2015
- 2016 (2) Apply 2016 filter
- 2017 (3) Apply 2017 filter
- (-) Remove 2018 filter 2018
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (0)
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (0)
- Literature Review (2) Apply Literature Review filter
- Portfolio Review (1) Apply Portfolio Review filter
- Research Brief (0)
Geography
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (2) Apply South Asia Region and Selected Countries filter
- Southern Africa Region and Selected Countries (0)
- (-) Remove Sub-Saharan Africa filter Sub-Saharan Africa
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (1) Apply Other Datasets filter
Current search
- (-) Remove 2010 filter 2010
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
- (-) Remove 2015 filter 2015
- (-) Remove Sub-Saharan Africa filter Sub-Saharan Africa
- (-) Remove 2008 filter 2008
- (-) Remove Global filter Global
- (-) Remove East Africa Region and Selected Countries filter East Africa Region and Selected Countries
- (-) Remove Health filter Health
- (-) Remove 2018 filter 2018
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
This report reviews the current body of peer-reviewed scholarship exploring the impacts of morbidity on economic growth. This overview seeks to provide a concise introduction to the major theories and empirical evidence linking morbidity – and the myriad different measures of morbidity – to economic growth, which is defined primarily in terms of gross domestic product (GDP) and related metrics (wages, productivity, etc.). Through a systematic review of published manuscripts in the fields of health economics and economic development we further identify the most commonly-used pathways linking morbidity to economic growth. We also highlight the apparent gaps in the empirical literature (i.e., theorized pathways from morbidity to growth that remain relatively untested in the published empirical literature to date).
This brief analyzes the indicators used by the World Bank in its Project Appraisal Documents (PAD) to measure the outputs and outcomes of 44 Water, Sanitation and Hygiene projects in Africa and Asia from 2000-2010. This report details the methods used to collect and organize the indicators, and provides a brief analysis of the type of indicators used and their evolution over time. A searchable spreadsheet of the indicators used in this analysis accompanies this summary. We find that some patterns emerge over time, though none are very drastic. The most common group of indicators used by the World Bank are “management” oriented indicators (28% of indicators). Management indicators are disproportionately used in African projects as compared to projects in Asia. Several projects in Africa incorporate indicators relating to legal/regulatory/policy outcomes, while projects in Asia do not. In recent years, the World Bank has used fewer indicators that measure service delivery, health, and education and awareness.